# Cullgen

Cullgen is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** cullgen.com
- **LinkedIn:** https://www.linkedin.com/company/cullgen

## Regulatory record

- **Reports private funds:** No

## About

Powering protein degradation for tomorrow's medicines | Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands.

## Sectors

- Biotech & Pharmaceuticals

## Offices

- Tokyo, Japan
- Shanghai, China

## People

- Ying Luo — Chief Executive Officer
- Jin Wang — Chief Scientific Officer

## Questions

### What is Cullgen’s relationship to Anji Pharma?

Anji Pharma operates as a subsidiary of Cullgen, created to independently advance select clinical-stage programs, particularly those with near-term regulatory pathways. This structure allows the parent company to maintain focus on its preclinical degradation pipeline while enabling Anji Pharma to pursue a separate development and financing strategy. The arrangement is unusual among early-stage protein-degradation biotechs and reflects a modular approach to managing platform risk versus clinical attrition risk.

### Which therapeutic areas and targets does Cullgen prioritize?

Cullgen prioritizes oncology as its lead therapeutic area, with additional programs in inflammatory and immune-mediated diseases. The company has not publicly disclosed a full target list, but its Astellas Pharma partnership focuses on immuno-oncology applications of targeted protein degradation. The firm’s public statements indicate an emphasis on historically undruggable intracellular targets, the same class that attracted large pharma interest to the degradation modality broadly.

### What is Cullgen’s competitive posture relative to larger protein-degradation peers like Arvinas or Kymera?

Cullgen competes with larger, US-headquartered protein-degradation companies such as Arvinas and Kymera Therapeutics, both of which are publicly traded and have clinical-stage assets. Cullgen’s differentiation rests on its Asian R&D footprint, its uSMITE platform’s screening approach to novel E3 ligases, and its subsidiary model via Anji Pharma. The firm’s competitive challenge is a narrower resource base relative to well-capitalized peers, making its reverse-merger public listing a consequential step for future head-to-head development timelines.

## Related profiles

- [Wonder Group](https://altss.com/profile/wonder-group)
- [Hilti Group](https://altss.com/profile/hilti-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cullgen-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology